Pazopanib

Tablet: 800mg

• To be taken 1 hour before or 2 hours after meals

Tyrosine Kinase Inhibitor anticancer

It inhibits multiple tyrosine kinases including VEGF, resulting in decreased angiogenesis, tumor growth and cancer progression

• Diarrhea
• Hypertension
• Fatigue
• Nausea
• Hair discoloration
• Decreased weight
• Vomiting
• Hepatotoxicity
• Hemorrhage
• Dysgeusia
• Headache
• Tumor pain
• Myocardial dysfunction
• Anorexia
• Musculoskeletal pain
• Myalgia
• Alopecia
• Dyspnea
• Rash
• Cough
• Asthenia
• Chest pain
• Skin depigmentation
• Peripheral edema
• Abdominal pain
• Dyspepsia
• Dysphonia
• Mucositis
• Proteinuria
• Dizziness
• Stomatitis
• Hypothyroidism
• Insomnia
• Epistaxis
• Hand-foot syndrome
• Venous thromboembolism
• Xeroderma
• Rigors
• Blurred vision
• Nail disorder
• QT prolongation
• MI
• Increased ALT/AST
• Increased glucose
• Leukopenia
• Lymphocytopenia
• Thrombocytopenia
• Neutropenia
• Increased bilirubin
• Decreased sodium
• Hyperlipasemia

• Hypersensitivity to components/class
• Pediatric patients
• Electrolyte abnormalities
• Bilirubin >3x ULN
• Hemoptysis within 6 months
• GI hemorrhage within 6 months
• Cerebral hemorrhage within 6 months
• Stroke within 6 months
• MI within 6 months
• Uncontrolled hypertension
• GI perforation
• Fistula
• Unhealed surgical wound
• Major surgery within prior 2 weeks
• Avoid treatment for at least 1 week before elective surgery
• Avoid breastfeeding during treatment and for 2 weeks after discontinuation

WARNING:

Severe and fatal hepatotoxicity observed in clinical trials

• Aluminum hydroxide
• Atorvastatin
• Chloroquine
• Elagolix
• Lefamulin
• Cidofovir
• Cisapride
• Pimozide
• Thioridazine